Skip to main content
Deutsch

Overview current studies

  1. Department of Clinical Pharmacology
  2. Research
  3. Study participants
  4. Overview current studies

We are looking for volunteers

Bedaquilin Study

drug levels in the blood

Pharmacokinetics (=drug levels in the blood), safety and tolerability when administering a long-acting injection of bedaquiline into the muscle.

The aim of this study is to find out how long the drug bedaquiline remains in and affects your body. This is done by measuring your blood and urine.

Prerequisites:    

  • Male or female (unable to give birth)
  • age under 60 years
  • physical health
  • no long-term medication


Study duration/time required: 52 weeks

A total of 24 appointments: including one preliminary examination, 2 overnight stays at the start of the study, a further 22 appointments (approx. 1 hour each) spread over 1 year

Financial compensation !

 

Maria Weber

Detailed information about the study programme:
AKH, Floor 6 "Leitstelle L"
Klinische Pharmakologie
Room No: 6L 0.04 
Maria Weber

Tel. Nr.: +43 1 40400 29970
Mail: maria.weber@meduniwien.ac.at

Study on the COVID-19 booster vaccination

Vaccination protection

The Department of Clinical Pharmacology is looking for people between the ages of 18-64 who received a COVID-19 booster vaccination (virus variant JN.1) between 19/09/2024 and 20/10/2024 (e.g. MedUni Vienna vaccination campaign on 24/25 September, 01/02 October). The aim of the study is to analyse the breadth and extent of vaccination protection against different virus variants in the laboratory.

Important exclusion criteria: COVID-19 infection in the last 180 days, immunosuppression

Time required: max. 20 minutes

Procedure: One-time blood sample (max. 10 ml), expense allowance

Link to make an appointment: https://www.eTermin.net/klinpharm

Please take your vaccination certificate with you!

 

Drug trial for weight loss ‘Diabetes type 2’

A new drug is currently being tested for its effect on type 2 diabetes patients. Our team is evaluating the effect on weight, blood glucose levels, liver fat content and glycogen (stored glucose).

We are looking for participants (m/f/d):

  • Age: between 18 and 65 years,
  • Previous illness: type 2 diabetes
  • Overweight (BMI 27 to 39.9)
  • Non-smokers

Participation is not possible with:

  • active insulin therapy
  • Taking more than 2 other medications for diabetes in tablet form
  • Severe vascular disease
  • Type 1 diabetes
  • Cancer diagnosis in the last 10 years (exception: light skin cancer)
  • Use of preparations for weight reduction
  • Contraindications for MRT

Duration of treatment: 25 weeks
Your expenses will be financially compensated

Carola Fuchs